U.S. Markets close in 2 hrs 27 mins

Exelixis’s Cabometyx Receives New Treatment Recommendations

Daniel Collins
Exelixis’s Cabometyx Receives New Treatment Recommendations

Today, Exelixis announced that the NCCN (National Comprehensive Cancer Network) had updated its clinical practice guidelines, in which it recommended Cabometyx tablets for the treatment of individuals with advanced renal cell carcinoma irrespective of the patient’s risk status. The NCCN’s clinical practice guidelines for kidney cancer now recommend Cabometyx as the only preferred TKI (tyrosine kinase inhibitor) therapy in treatment-naïve patients who are in the poor to intermediate risk group.